A Trial of FHD-286 Plus Mosunetuzumab in Previously Treated Follicular Lymphoma
Key facts
- Who runs it
- Weill Medical College of Cornell University
- Where
- New York, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 22 people, planned
- Started
- Nov 2026
- Expected to end
- Dec 2031
- Type of study
- Interventional, 4 groups
- Treatments tested
- Mosunetuzumab
- FHD-286
- Record updated
- 17 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Histologically confirmed diagnosis of FL
- FL meeting criteria for initiation of systemic therapy per treating investigator and institutional standards
- Eligible for SOC mosunetuzumab, which is currently FDA approved in FL after at least two prior lines of therapy
- Age ≥ 18 years
- ECOG performance status ≤ 2 (Appendix A)
- Required initial laboratory parameters:, Hemoglobin ≥ 7 g/dL; transfusions permissible at treating physician discretion. Absolute neutrophil count (ANC) ≥ 1000 cells/mm3. Platelet count ≥ 75,000 cells/mm3. Calculated creatinine clearance ≥ 45 ml/min by eGFR. Total bilirubin ≤ 1.5 x ULN. AST, ALT, and ALP ≤ 2.5 x ULN
Who cannot take part
- Infection with HIV or hepatitis type B or C. Seropositive HBV patients are eligible if they are negative for HBV DNA by PCR and receive concomitant antiviral therapy during treatment and for additional six months after completion of therapy
- Ongoing treatment with a moderate or strong CYP3A inhibitor. These include, but are not limited to medications as follows. An additional list of prohibited medications is listed in Appendix E
- Major surgery within the preceding four months
- Ongoing treatment with steroids equivalent to > 20mg prednisone daily
- Active, uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment)
- Active treatment or being within two years of active treatment for a second malignancy, excluding non-melanomatous skin cancer
- Decompensated cardiac disease
- History of allogeneic bone marrow transplant
- Prolonged QTc interval, defined as a corrected QT interval (QTc) using Fridericia's formula (QTcF) > 470 msec
- Known or suspected central nervous system (CNS) involvement by lymphoma
- Any grade 3 or greater baseline AE
- Life expectancy < 6 months
- Evidence of transformation of FL
- Active immunosuppression
- Pregnant or breastfeeding
Where in United States
- Weill Cornell MedicineNew York, United StatesContact: Simone Morris, RNNot yet recruiting
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if FHD-286 in combination with mosunetuzumab is safe and tolerable for treating adults with previously treated relapsed/refractory follicular lymphoma. It will also evaluate how well the combination works and how it affects cancer-related molecular and immune markers.The main questions it aims to answer are:
Read full original descriptionShow less
* What is the maximum tolerated dose of FHD-286 when given in combination with mosunetuzumab? * Is the combination of FHD-286 and mosunetuzumab safe and tolerable? * How many participants have a response to treatment, and how long does the treatment control the disease? * How does treatment affect circulating tumor DNA (ctDNA), immune responses, and molecular markers, including BAF complex mutational status?
Researchers will evaluate FHD-286 in combination with mosunetuzumab in participants with relapsed or refractory follicular lymphoma to assess safety, tolerability, and preliminary anti-tumor activity.
The 4 groups in the trial
- Dose Level -1Treatment being tested
2.5mg FHD-286 daily
Treatment: Mosunetuzumab and FHD-286
- Dose Level 0Treatment being tested
5mg FHD-286 daily
Treatment: Mosunetuzumab and FHD-286
- Dose level +1Treatment being tested
7.5mg FHD-286 daily
Treatment: Mosunetuzumab and FHD-286
- Dose Level +2Treatment being tested
10mg FHD-286 daily
Treatment: Mosunetuzumab and FHD-286
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase Ib Trial of FHD-286 Plus Mosunetuzumab in Previously Treated Follicular Lymphoma
- Record updated
- 17 November 2026